IDORSIA AG NAMENS-AKTIEN SF-,05

Zeit	Titel
03.06. 07:05	GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024
31.05. 07:05	GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society ...
23.05. 07:05	GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
21.05. 07:05	GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21.05. 06:55	GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company...
21.05. 06:45	GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company t...
14.05. 17:50	GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and con...
06.05. 18:40	GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds
01.05. 18:05	GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the...
26.04. 07:05	GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resista...
23.04. 07:05	GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting
17.04. 07:05	GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting
11.04. 07:05	GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs
22.03. 07:05	GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires
20.03. 07:05	GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endoth...
18.03. 07:05	GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and dev...
28.02. 07:05	GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collabora...
10.01. 07:05	GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for susta...
03.11. 22:35	GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been p...
24.10. 07:05	GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des ...

2024 Infront Financial Technology GmbH
Impressum